PET tracer development for imaging α-synucleinopathies

Area of Science:

• Neuroscience
• Radiochemistry
• Molecular Imaging

Background:

• Abnormal alpha-synuclein (α-synuclein) aggregation defines α-synucleinopathies, including Parkinson's disease (PD) and multiple system atrophy (MSA).
• These conditions involve targeted neurodegeneration and Lewy body pathology, contributing to disease progression.
• Current diagnostic and therapeutic strategies for α-synucleinopathies are limited by the lack of specific biomarkers.

Purpose of the Study:

• To review the current state of α-synuclein positron emission tomography (PET) tracer development.
• To discuss the potential of PET imaging in early diagnosis, drug development, and disease monitoring for α-synucleinopathies.
• To explore future directions in the field of α-synuclein PET imaging.

Main Methods:

• Focuses on the design and application of α-synuclein-targeted radiolabeled probes for in vivo imaging.
• Utilizes positron emission tomography (PET) as a non-invasive imaging modality.
• Summarizes recent research and ongoing efforts in developing selective PET tracers.

Main Results:

• α-synuclein PET tracers target fibrillar α-synuclein aggregates, enabling visualization of neuropathology.
• PET imaging offers a pathway for early diagnosis and assessment of treatment efficacy in α-synucleinopathies.
• Significant progress has been made in understanding PD mechanisms through PET biomarker advancements.

Conclusions:

• Development of selective α-synuclein PET tracers is essential for clinical applications in diagnosing and managing α-synucleinopathies.
• In vivo detection of α-synuclein aggregates via PET holds promise for accelerating drug discovery and improving patient care.
• Continued research in PET tracer development is critical for advancing the understanding and treatment of these neurodegenerative disorders.